TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceTransMedics has huge opportunities ahead but also a few challenges and moving dynamics, which were factored into realistic guidance
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics achieved its best operational performance to date despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceTransMedics achieved our best operational performance to date with these results achieved despite external challenges earlier in the year that were designed to distract and disrupt our sustained and transformational growth
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics is laser-focused on ensuring successful execution of 2026 initiatives
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceThe makers of that styrofoam box is refusing to randomize their technology to ours in ENHANCE Part B
80% confidenceResults were achieved despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4 2025
80% confidenceWe are not seeing competitive dynamic impacting our ability to execute in 2026 and beyond
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceOCS Liver market share gains represent pure TransMedics execution excellence
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceAlmost 50% of the incremental investment in 2026 is driven by really 3 elements and those, by nature, are transitory
80% confidenceTransMedics is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million in Q4 2025
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceMost of the lung centers were waiting to see the FDA approval to start launching into DENOVO
80% confidenceThe makers of that styrofoam box (competitor) is refusing to randomize their technology to TransMedics in ENHANCE Part B trial
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceOperating margins are expected to approach 30% by 2028
80% confidence2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments
80% confidence